Immunovant (IMVT) COO offloads 2,036 shares to cover RSU tax withholding
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Immunovant, Inc. Chief Operating Officer Gloria Melanie reported two open-market sales totaling 2,036 shares of common stock on July 8, 2026. According to the disclosure, these shares were sold solely to cover tax withholding obligations arising from the July 1, 2026 vesting and settlement of previously granted restricted stock units, under a mandated “sell to cover” arrangement rather than a discretionary trade.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 2,036 shares ($80,532)
Net Sell
2 txns
Insider
Gloria Melanie
Role
Chief Operating Officer
Sold
2,036 shs ($81K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 1,930 | $39.53 | $76K |
| Sale | Common Stock | 106 | $39.99 | $4K |
Holdings After Transaction:
Common Stock — 222,463 shares (Direct)
Footnotes (1)
- On April 1, 2025, the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported on a Form 4 filed on April 3, 2025, of which 4,761 of these RSUs vested on July 1, 2026. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.91 - $39.89 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.92 - $40.03 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Key Figures
Total shares sold: 2,036 shares
First transaction weighted average price: $39.53 per share
Second transaction weighted average price: $39.99 per share
+4 more
7 metrics
Total shares sold
2,036 shares
Open-market sales on July 8, 2026 to cover tax withholding
First transaction weighted average price
$39.53 per share
Common stock sale of 1,930 shares
Second transaction weighted average price
$39.99 per share
Common stock sale of 106 shares
RSU grant size
76,181 RSUs
Restricted stock units granted on April 1, 2025
RSUs vested
4,761 RSUs
Portion of the grant that vested on July 1, 2026
First sale price range
$38.91–$39.89 per share
Multiple executions aggregated into a weighted average price
Second sale price range
$39.92–$40.03 per share
Multiple executions aggregated into a weighted average price
Key Terms
restricted stock units ("RSUs"), sell to cover, weighted average price, tax withholding obligations
4 terms
restricted stock units ("RSUs") financial
"the holder was granted 76,181 restricted stock units ("RSUs"), as previously reported"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
sell to cover financial
"tax withholding obligations to be funded by a "sell to cover" transaction"
Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.
weighted average price financial
"The price reported is a weighted average price. These shares were sold in multiple transactions"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
tax withholding obligations financial
"shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting"
FAQ
What did Immunovant (IMVT) COO Gloria Melanie report in this Form 4?
Immunovant (IMVT) COO Gloria Melanie reported selling 2,036 shares of common stock on July 8, 2026. The transactions were open-market sales executed to cover tax withholding obligations from vested RSUs.
What RSU grant is referenced in the Immunovant (IMVT) Form 4 filing?
The filing references a grant of 76,181 restricted stock units (RSUs) awarded on April 1, 2025. Of these, 4,761 RSUs vested on July 1, 2026, triggering the related tax-withholding share sales.
Were the Immunovant (IMVT) COO’s sales part of a trading plan?
The filing explains the sales were mandated as a “sell to cover” for tax withholding on vested RSUs. It characterizes them as non-discretionary, driven by the issuer’s election on how to satisfy tax obligations.
How were the sale prices determined in the Immunovant (IMVT) COO transactions?
Each transaction’s reported price is a weighted average price. The shares were sold in multiple executions within ranges of $38.91–$39.89 and $39.92–$40.03 per share, respectively.